Global Blood Therapeutics, INC.
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersSouth San Francisco, CA
US patents56
SAM.gov UEIH4LLV5LPHA37
CAGE code75SU5
Incorporated inDE
LEI549300U4G0QKK99GRT15
Supplier designations
For Profit OrganizationManufacturer of Goods
Self-certified by the company in its SAM.gov registration
Patents
56 US patents granted 2015–2025, 24 of them in the five years to SEP 2025.
Pharmaceuticals 29Organic fine chemistry 27
- Cycloalkyl pyrimidines as ferroportin inhibitorsUS 12,202,817 · granted JAN 21, 2025
- Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehydeUS 11,944,612 · granted APR 2, 2024
- Methods of making a modulator of hemoglobinUS 11,939,323 · granted MAR 26, 2024
- Solid forms of a modulator of hemoglobinUS 11,851,424 · granted DEC 26, 2023
- Cycloalkyl pyrimidines as ferroportin inhibitorsUS 11,746,100 · granted SEP 5, 2023
Newest 5 shown · Granted to Global Blood Therapeutics, Inc. · PatentsView (USPTO), data through SEP 30, 2025 · CC BY 4.0
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Global Blood Therapeutics, INC. | South San Francisco | CA | — | LIKELY ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.